论文信息 - Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

This cross-sectional study examines trends in costs of brand-name medications for treatment of non–small cell lung cancer and within-class price differences between these medications in the US from 2015 to 2020.

[1] A. Kesselheim,et al. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs , 2021, JAMA network open.

[2] W. Gellad,et al. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018. , 2020, JAMA.

[3] A. Kesselheim,et al. Competition and price among brand-name drugs in the same class: A systematic review of the evidence , 2019, PLoS medicine.

[4] Bingshu E. Chen,et al. The economic impact of the transition from branded to generic oncology drugs. , 2016, Current oncology.

[5] Ashley L Cole,et al. Generic Price Competition For Specialty Drugs: Too Little, Too Late? , 2018, Health affairs.

[6] D. Goldstein,et al. Trajectories of Injectable Cancer Drug Costs After Launch in the United States. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] J. Dunn,et al. How drug life-cycle management patent strategies may impact formulary management. , 2017, The American journal of managed care.

[8] P. Newcomb,et al. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9] Vinay Prasad,et al. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. , 2015, JAMA oncology.